Explore the PD-L1 Pathway

Building on the foundation of PD-L1 pathway inhibition

We are continuing to advance the understanding of cancer immunotherapy by researching pathways that can be targeted simultaneously with the PD-L1/PD-1 pathway to address various immune escape mechanisms in cancer.

As a scientifically validated approach to reinvigorating the antitumor immune response, PD-L1 pathway inhibition has taken an important role in restoring a key part of the cancer immunity cycle.1

PD-L1=programmed death-ligand 1.

Immune Escape

PD-L1 and the MAPK Pathway

PD-L1 Inhibition + VEGF Inhibition

PD-L1 Inhibition + Antigen Release


Antibodies icon

Emerging development platforms

Discover our broad range of antitumor modalities.

Microscope icon

Discover cancer biomarkers

Learn more about the importance of cancer biomarkers.